Schering-Plough results clarification
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas pointed out that, on a GAAP basis, the decrease in its group income was largely due to charges of $354 million from purchase accounting adjustments and $94 million of special and acquisition-related charges. The cancellation of its respiratory programme with Merck & Coon a Claritin/Singulair combination resulted in a benefit to equity income of $64 million.